Overview

Clarithromycin + Lenalidomide Combination: a Full Oral Treatment for Patients With Relapsed/Refractory Extranodal Marginal Zone Lymphoma

Status:
Active, not recruiting

Trial end date:
2029-11-01

Target enrollment:

Participant gender:

Summary

Patients with lymphoid tissue lymphoma mucosa-associated (MALT) for which the standard treatments with radiotherapy, chemotherapy and / or immunotherapy show lack of efficacy

Phase:

Phase 2

Details

Lead Sponsor:

International Extranodal Lymphoma Study Group (IELSG)

Treatments:

Clarithromycin
Lenalidomide
Thalidomide